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Failure to eradicate cancer stem cells (CSC) during primary therapy may lead to 31 
cancer recurrence. We recently reported that CD133 is a functional biomarker for CSCs in 32 
esophageal squamous cell carcinoma (ESCC) but the molecular pathways critical for 33 
maintenance of CD133-positive CSCs are largely unknown. Here, we revealed that 34 
knockdown of IGF2 or treatment with PI3K/AKT inhibitors markedly inhibited the abilities 35 
of CD133-positive ESCC cells to self-renew, resist chemotherapeutic drugs, and form tumors. 36 
Further functional analysis identified miR-377 as a downstream regulator of PI3K/AKT 37 
signaling, and a mediator of the effects of IGF2 on CD133 expression and CSC properties. 38 
We found that the expression levels of IGF2 and CD133 were positively correlated with each 39 
other in primary ESCC, and that concurrent elevation of IGF2 and CD133 expression was 40 
significantly associated with poor patient survival. Furthermore, in vivo experiments 41 
demonstrated that IGF2-neutralizing antibody enhanced the sensitivity of tumor xenografts in 42 
nude mice to 5-fluorouracil treatment. This study underpins the importance of the IGF2-43 
PI3K/AKT-miR-377-CD133 signaling axis in the maintenance of cancer stemness and in the 44 
development of novel therapeutic strategy for treatment of esophageal cancer. 45 
 46 




1. Introduction 49 
Esophageal cancer is the one of the deadliest and least studied cancers worldwide. 50 
The prognosis is very poor and the 5-year survival rate is less than 20% [1]. However, the 51 
precise mechanisms and genetic underpinnings of this disease remain to be fully elucidated. 52 
Therefore, there is an urgent need to test novel biomarkers for diagnostic and prognostic 53 
significances, and to explore their potentials as therapeutic targets. 54 
The existence of cancer cells with stem-like properties that have the capacity to resist 55 
conventional chemoradiotherapy and to self-renew is one of the major challenges in cancer 56 
treatment. Previous studies have established a link between chemoresistance and cancer stem 57 
cells (CSCs) phenotype [2, 3]. CD133 is a five transmembrane domain cell surface 58 
glycoprotein originally found on neuroepithelial stem cells in mice [4]. CD133 has been used 59 
as a marker to isolate CSCs from diverse solid tumors such as hepatocellular carcinoma [5] 60 
and colon cancer [6]. CD133 has also been reported to be associated with worse overall 61 
survival and higher recurrence rates in several cancer types [5, 7, 8]. There are very few 62 
reports regarding the significance of CD133 in the context of esophageal cancer. In our recent 63 
study, we provided the first evidence that CD133 is a functional CSC marker for esophageal 64 
squamous cell carcinoma (ESCC) [9]. However, we are still far from fully understanding the 65 
molecular mechanisms that drive CSC maintenance in ESCC. 66 
Insulin-like growth factors (IGF) play important roles in many tumor proliferation, 67 
growth, differentiation, and angiogenesis, and are therefore regarded as promising targets in 68 
cancer therapy [10, 11]. Although insulin-like growth factors 1 (IGF1) and insulin-like 69 
growth factor 2 (IGF2) share about 70% homology in amino acid sequence, they each have 70 
their distinct functions.  In our previous studies, we showed that overexpression of Inhibitor 71 
of Differentiation 1 (Id1) induces the expression of IGF2, which can promote cancer 72 
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progression in both autocrine and paracrine manners [12, 13]. However, the functional role 73 
and mechanism of IGF2 in tumor initiation and cancer stemness remain to be elucidated. In 74 
the present study, we determined if IGF2 is functionally required for the maintenance of CSC 75 
properties in ESCC cells by performing in vitro and in vivo experiments to study its effects on 76 
the stem cell marker CD133 and CSC phenotypes including chemoresistance, tumor initiation 77 
and self-renewal. Whether blockade of IGF2 signal with neutralizing antibody could suppress 78 
the ability of ESCC cells to form spheres in vitro and tumors in vivo was also examined. 79 
  80 
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2. Materials and Methods 81 
2.1 Cell culture and drugs 82 
Human ESCC cell lines KYSE270 (DSMZ, Braunschweig, Germany) [14] and T.Tn [15] 83 
were maintained in RPMI 1640 (Sigma, St. Louis, MO, USA) supplemented with 10% fetal 84 
bovine serum (Invitrogen, Gaithersburg, MD, USA) at 37ºC in 5% CO2. Human recombinant 85 
IGF2 was purchased from Invitrogen. Wortmannin, LY294002, 5-fluorouracil (5-FU) and 86 
cisplatin, purchased from Calbiochem (Darmstadt, Germany), were dissolved in dimethyl 87 
sulfoxide (DMSO).  88 
 89 
2.2 Transfection, transduction, and establishment of stable cell lines 90 
The miR-377 mimic and negative control, and the anti-miR-377 inhibitor and corresponding 91 
negative control, were purchased from Thermo Scientific Ambion (Austin, TX, USA). The 92 
plasmid expressing phosphatase and tensin homolog (PTEN), i.e. pcDNA3-PTEN [16], and 93 
the vector control pcDNA3-GFP [17] were gifts from William Sellers (Dana Faber Cancer 94 
Institute, Boston, MA, USA) and Alonzo Ross (University of Massachusetts, Worcester, MA, 95 
USA), respectively (Addgene plasmids 10759 and 20738; Addgene, Cambridge, MA, USA). 96 
Transfection and establishment of stable cell lines with knockdown of IGF2 were performed 97 
as described previously [18], and stable cell lines were obtained after further selection with 98 
puromycin. 99 
 100 




 populations by flow cytometry  101 
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Cell sorting was performed as described previously [9]. In brief, cells were stained with 102 
phycoerythrin (PE)-conjugated anti-human CD133 antibody (Miltenyi Biotec, Bergisch 103 
Gladbach, Germany) or with isotype control mouse IgG1-PE (Miltenyi Biotec), and then 104 
analyzed and sorted on BD FACS Aria I (BD Biosciences, San Jose, CA). The top 20% of 105 
most brightly stained cells and the bottom 20% of most dimly stained cells were selected as 106 
positive and negative populations, respectively.  107 
 108 
2.4 Western blot 109 
Preparation of cell and tumor lysates, and details of western blotting were described 110 
previously [19]. The primary antibodies used included phospho-AKT (Ser473), AKT and  111 
PTEN obtained from Cell Signaling Technology (Beverly, MA), IGF2 (R&D Systems, 112 
Minneapolis, MN, USA), CD133 (Miltenyi Biotec), and actin  from Santa Cruz 113 
Biotechnology (Santa Cruz, CA, USA). 114 
 115 
2.5 Quantitative real-time PCR (qRT-PCR) 116 
Total RNA was isolated using Trizol reagent according to the manufacture’s protocol 117 
(Invitrogen). Expression levels of miR-377 and U6 (internal control) were detected using 118 
Taqman microRNA reverse transcription kit and Taqman miRNA assays (Applied 119 
Biosystems, Carlsbad, CA, USA) as described previously [9]. All the experiments were 120 
performed on MyIQTM2 Real-Time PCR Detection System (Bio-Rad, Hercules, CA, USA). 121 
 122 
2.6 MTT assay 123 
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MTT assay was carried out as described previously [20]. The absorbance was measured at a 124 
wavelength of 570 nm on a Labsystems Multiskan microplate reader (Merck Eurolab, 125 
Dietikon, Switzerland). 126 
 127 
2.7 Sphere-formation assay  128 
Sphere-formation assay was carried out as described previously [9]. In brief, ESCC cells 129 
were seeded onto polyHEMA (Sigma)-coated 6-well-plates, and grown in DMEM/F12 130 
(Invitrogen) medium containing various growth factors. For serial passaging, the spheres 131 
were collected and dissociated into single cells, and then re-suspended in the above medium 132 
to culture next-generation spheres. 133 
 134 
2.8 Tumorigenicity in nude mice 135 
All the animal experiments were approved by the Committee on the Use of Live Animals in 136 
Teaching and Research, the University of Hong Kong, or Jinan University. Female BALB/c 137 
nude mice aged 6-8 weeks were used. Tumor xenograft experiments and determination of 138 
tumor volume were performed as described previously [21]. In the wortmannin experiment, 139 
the mice were randomized into treatment and control groups when the subcutaneous tumors 140 
reached ~5 mm diameter, and then injected intraperitoneally with wortmannin (0.6 mg/kg, 141 
every three days) and DMSO, respectively. In the IGF2 immunoneutralization experiment, 142 
groups of mice (n = 6/group) received twice weekly intratumoral injections of the 143 
neutralizing antibody against human IGF2 (Anti-IGF2, 10 μg/cm
3
 tumor; R&D Systems), 144 
intraperitoneal injections of 5-FU (20 mg/kg), or anti-IGF2 combined with 5-FU, whereas the 145 
control group received DMSO or the isotype IgG. Tumors were collected at the end of 146 
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experiments. Those animals engrafted with cancer cells but with no sign of tumor burden 147 
were sacrificed and dissected 3 months after tumor cell inoculation to confirm that there was 148 
no tumor development. 149 
 150 
2.9 Patient samples 151 
Use of all human samples was approved by the committees for ethical review of research 152 
involving human subjects at the Queen Mary Hospital in Hong Kong and Zhengzhou 153 
University in Zhengzhou. 154 
 155 
2.10 Tissue microarray and immunohistochemistry 156 
A tissue microarray containing 100 cases of human ESCC (1 core/case) of which 80 had 157 
matched normal adjacent tissue (1 core/case) on the same slide (#HEso-Squ180Sur-04, 158 
Shanghai Outdo Biotech, Shanghai, China) was used to determine the correlation between 159 
IGF2 and CD133 expressions, and to evaluate the clinical significance of the two proteins in 160 
ESCC. After antigen retrieval and blocking with normal serum, the slides were incubated 161 
overnight at 4 ºC with the primary antibody against IGF2 (R&D Systems) or CD133 162 
(Miltenyi Biotec), followed by biotinylated secondary antibodies and peroxidase-conjugated 163 
avidin-biotin complex (DAKO Diagnostics, Mississauga, ON, USA). Immunostaining was 164 
visualized using 3, 3’-diaminobenzidine (DAKO) as chromogen, and then the sections were 165 
counterstained with hematoxylin. Evaluation of IGF2 immunostaining was performed as 166 
described previously [12]. The sections were examined by two independent observers who 167 
were blinded to the patients’ clinical information. Specimens assigned scores of 0 to 1 were 168 
categorized as low expression, whereas scores 2 to 3 were considered high expression. 169 
CD133 immunostaining in the TMA was evaluated in random fields under × 400 170 
10 
 
magnification. Tumors with > 1% of the tumor cells showing positive staining in the 171 
membrane and cytoplasm were defined as CD133-positive [22, 23]. Normal esophageal 172 
epithelium was scored according to the same criteria. 173 
 174 
2.11 Analysis of TCGA data 175 
Data sets were downloaded from LinkedOmics (http://www.linkedomics.org), which is a 176 
publicly available portal that includes multi-omics data from all 32 cancer types from The 177 
Cancer Genome Atlas (TCGA) project.  178 
 179 
2.12 Statistical analysis  180 
All in vitro experiments and assays were repeated at least three times, and the data were 181 
expressed as the mean ± SD and compared using ANOVA. The correlation between the 182 
expression levels of IGF2 and CD133, and that between IGF2 and miR-377 were assessed 183 
using Pearson rank correlation coefficient. Correlations between IGF2 or CD133 and 184 
clinicopathological parameters were determined using Fisher exact test. The association 185 
between IGF2/CD133 expressions and patient survival was plotted using the Kaplan-Meier 186 
method, and statistical differences were compared using the log-rank test. Univariate and 187 
multivariate survival analyses were performed using the Cox proportional hazard model with 188 
a forward stepwise procedure (the entry and removal probabilities were 0.05 and 0.10, 189 
respectively). P values < 0.05 were deemed significant.  190 
  191 
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3. Results 192 
3.1 IGF2 is essential for tumor initiation and self-renewal in ESCC  193 
The role of IGF2 in inducing CSC phenotype is still unclear. The significant effect of IGF2 in 194 
promoting chemoresistance in ESCC cells [18] prompted us to determine whether IGF2 is 195 
functionally crucial for maintenance of CSC properties. KYSE270 cells with IGF2-196 
knockdown (designated KYSE270-shIGF2#2) and control cells expressing non-effective 197 
shRNA (i.e. KYSE270-shCON) were injected subcutaneously into the flanks of nude mice 198 
for comparison of tumor-initiating ability. Our results showed that even though both 199 
KYSE270-shIGF2#2 and KYSE270-shCON cell lines formed tumors in all the mice in the 200 
respective groups (n = 6) at a cell dose of 1x10
5
, the tumors in the former group were 201 
significantly smaller (Figure 1A). At a lower cell dose of 2x10
4
, KYSE270-shIGF2 cells 202 
formed tumors in only three out of six mice (50.0%), whereas KYSE270-shCON cells 203 
produced tumors in all six mice in the group (100%) (Figure 1B), indicating that IGF2 is 204 
essential for ESCC tumorigenesis. Moreover, inoculation of the same number (i.e. 2x10
4
) of 205 
resuspended cancer cells from excised primary xenografts into secondary mouse recipients 206 
produced similar results (Figure 1B), which suggests that IGF2 has a functional role in 207 
maintaining the sphere-forming and tumorigenic potential of ESCC cells. To further examine 208 
the significance of IGF2 in regulating CSC properties in ESCC, we determined the effects of 209 
exogenous IGF2 on the ability of KYSE270 and T.Tn cells to form spheres over serial 210 
passages in non-adherent, serum-free, growth factor-supplemented medium. As shown in 211 
Figure 1C, IGF2 stimulated ESCC cells to form spheres in first and second passages, but 212 
these effects were abrogated by simultaneous addition of a PI3K inhibitor, LY294002. The 213 
reduced capacity of KYSE270 and T.Tn cells with IGF2-knockdown to undergo serial 214 
propagation under sphere-formation culture conditions further confirmed that IGF2 is 215 
important for maintaining cancer stemness in ESCC (Figure 1D). Moreover, exposure to 216 
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IGF2 significantly increased CD133 expression in ESCC cells, and these effects were 217 
abrogated by LY294002 (Figure 1E). Conversely, knockdown of IGF2 significantly 218 
inhibited the expression level of CD133 (Figure 1F). Collectively, these results demonstrated 219 
that IGF2 is essential for maintenance of CSC properties in ESCC cells. 220 
 221 
3.2 PI3K/AKT inhibition decreases CD133 expression and suppresses CSC phenotypes 222 
of CD133
+
 ESCC cells 223 
Since both CD133 [9] and phosphorylated AKT (p-AKT) expressions were increased in 224 
sphere-forming ESCC cells compared with their differentiated adherent counterparts (Figure 225 
2A), we hypothesized that blockade of PI3K/AKT may suppress the CSC phenotypes of 226 
CD133
+
 ESCC cells. We treated ESCC cells with two specific inhibitors of PI3K (i.e. 227 
wortmannin and LY294002) which were verified to produce dose-dependent inhibition of p-228 
AKT (Figure 2B), and the results showed that PI3K/AKT inhibition not only reduced CD133 229 
expression (Figure 2B), but also the serial sphere-formation ability of ESCC cells 230 
(Supplementary Figure S1A). Transfecting the cells with the vector expressing PTEN 231 
produced similar results (Figure 2C and Supplementary Figure S1B). We then examined 232 
whether inactivation of the PI3K/AKT pathway could preferentially target and inhibit the 233 
stemness of CD133
+
 ESCC CSCs. Compared with sorted CD133
-
 ESCC cells, CD133
+
 cells 234 
were more responsive to wortmannin and LY294002 treatment (Figure 2D), and their ability 235 
to form spheres and to serially propagate in vitro was significantly suppressed by these 236 
inhibitors (Figure 2E). Wortmannin and LY294002 also reduced the expression level of 237 
CD133 in the sorted CD133
+
 cells (Figure 2F). More importantly, growth of tumor 238 
xenografts derived from CD133
+
 ESCC cells was significantly suppressed in nude mice 239 
treated with wortmannin (Figure 2G). We next studied the effects of PI3K/AKT inhibition 240 
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on the chemosensitivity of CD133
+ 
CSCs. The data from sphere-formation assays showed 241 
that PI3K/AKT inhibition rendered the CD133
+
 ESCC cells more sensitive to 5-FU and 242 
cisplatin (DDP) treatment (Figure 2H). Taken together, the above findings substantiate that 243 
blockade of PI3K/AKT pathway could reduce the stemness of CD133
+ 
esophageal CSCs. 244 
 245 
3.3 MiR-377 upregulated by PI3K/AKT inhibition mediates the effects of IGF2 on 246 
CD133 expression and CSC properties 247 
Our recent study showed that miR-377, which can suppress the initiation of esophageal 248 
cancer by inhibiting CD133, is underexpressed in ESCC [9]. The mechanisms that 249 
downregulate miR-377 in ESCC had not been explored. Quantitative real time PCR (qRT-250 
PCR) data indicated that PI3K/AKT inhibition increased the expression level of miR-377 in 251 
ESCC cells (Figure 3A). On the other hand, addition of exogenous IGF2 significantly 252 
reduced miR-377 expression in ESCC cells, and these effects were abrogated by LY294002 253 
(Figure 3B). Conversely, knockdown of IGF2 expression resulted in an increase in miR-377 254 
expression (Figure 3C). Moreover, KYSE270-shIGF2#2 tumor xenografts had markedly 255 
higher expression level of miR-377 and lower expression level of CD133 compared with 256 
control tumors (Figure 3D). These results demonstrate that IGF2 can negatively regulate 257 
miR-377 and induce CD133 expression. In another experiment, KYSE270 and T.Tn cells 258 
transfected with miR-377 mimic or negative control (miR-CON) were treated with IGF2. 259 
Western blot data showed that IGF2 induced CD133 expression in ESCC cells transfected 260 
with miR-CON, but not in cells transfected with miR-377 (Figure 3E). Furthermore, we 261 
found that whereas IGF2-knockdown increased 5-FU chemosensitivity and decreased sphere-262 
forming ability of ESCC cells, transfection of miR-377 inhibitor significantly attenuated 263 
these effects (Figure 3F and 3G). Together, these results support that miR-377 plays a role 264 
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in mediating the effects of IGF2 on CD133 expression and CSC properties in ESCC cells. We 265 




 ESCC cell lines for the expression of IGF2-266 
PI3K/AKT-miR-377-CD133 signaling axis using Western blot and Taqman miRNA assay 267 
(Supplementary Figure S2B and 2C). The upregulation of IGF2 and p-AKT in the CD133
+ 
268 
cells, coupled with low miR-377 expression, strongly support the existence of a IGF2-269 
PI3K/AKT-miR-377-CD133 cascade in maintaining CSCs (Figure 3H).  270 
 271 
3.4 IGF2 is a promising therapeutic target for esophageal cancer 272 
We recently reported elevated IGF2 level in the serum of patients with ESCC [13]. We next 273 
evaluated IGF2 as a therapeutic target for ESCC by blocking it through immunoneutralization. 274 
Tumor-sphere formation of KYSE270 and T.Tn cells was measured in the presence of IGF2-275 
neutralizing antibody or isotype IgG control antibody. The results showed that IGF2-276 
neutralizing antibody exerted a significant dose-dependent inhibitory effect on the sphere-277 
forming capability of ESCC cells in vitro (Figure 4A). Tumorigenicity assay showed that 278 
treatment of tumor-bearing mice with IGF2-neutralizing antibody markedly suppressed 279 
growth of KYSE270 tumor xenografts (Figure 4B), as in the case of tumor xenografts 280 
established from another ESCC cell line KYSE150 [12], thus confirming that IGF2 supports 281 
tumorigenesis in ESCC. Similar to the findings in tumor xenografts derived from IGF2-282 
knockdown ESCC cells (Figure 3D), treatment with IGF2-neutralizing antibody significantly 283 
increased miR-377 expression and decreased expression level of CD133 (Figure 4C). We 284 
also evaluated the potential of IGF2-neutralizing antibody in combinational therapy for 285 
esophageal cancer. Nude mice with established subcutaneous tumor xenografts were treated 286 
with 5-FU and IGF2-neutralizing antibody alone or in combination, and the results showed 287 
that IGF2-neutralizing antibody markedly enhanced the sensitivity of tumor xenografts to 5-288 
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FU treatment (Figure 4D). These data suggest that immunoneutralization of IGF2 can render 289 
ESCC tumors more susceptible to 5-FU treatment.  290 
 291 
3.5 Clinical significance of immunohistochemical expression of IGF2 and CD133 in 292 
ESCC 293 
We reported previously that serum IGF2 level has prognostic value in ESCC [13] but whether 294 
the immunohistochemical expression level of this biomarker in ESCC tissue has diagnostic 295 
significance is not well documented. A tissue microarray containing 100 cases of ESCC and 296 
80 cases of tumor-adjacent normal esophageal tissue was immunostained for IGF2. Examples 297 
of ESCC with staining scores from 0 to 3 are shown in Figure 5A. As seen in Figure 5B, the 298 
expression of IGF2 in tumors was found to be higher than that in normal adjacent tissues. We 299 
then correlated IGF2 expression with clinicopathological parameters by stratifying the 100 300 
patients based on the expression level of IGF2 protein. The associations between IGF2 301 
protein expression and various clinicopathological parameters are presented in Table 1, 302 
which shows a significant correlation between high IGF2 expression and tumor (T) 303 
stage. Using the same tissue microarray, we further determined the expression of CD133 and 304 
its correlation with clinicopathological parameters (Figure 5C and Table 2). In contrast to 305 
normal tissue in which only 21.25% of the cases were positive for CD133, 45% of tumor 306 
samples were CD133-positive (Figure 5D). Furthermore, concurrent elevation of IGF2 and 307 
positive CD133 staining in the ESCC was associated with T3/T4 stages (Table 3).  308 
We then determined whether immunohistochemical IGF2 and CD133 expressions were 309 
associated with survival outcome. The data showed that the patients with low IGF2 310 
expression in the primary tumors had better survival outcome than those with high IGF2 311 
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expression (median survival: 25.0 vs 14.0 months; log rank test, P < 0.05) (Figure 5E, left 312 
panel). Our analysis also showed that patients with CD133-negative ESCC had much longer 313 
overall survival than those with CD133-positive tumors (median survival: 25.5 vs 13.0 314 
months; P < 0.05 (Figure 5E, middle panel). Notably, patients with concomitant high IGF2 315 
and positive CD133 expression had a median survival time of only 9.0 months, which was 316 
significantly shorter than that of patients with low IGF2 and negative CD133 expression 317 
(median survival = 26.0 months) (Figure 5E, right panel). Moreover, multivariate analysis 318 
showed that concomitant high IGF2 and positive CD133 expression in tumor was an 319 
independent prognostic factor for overall survival (Table 4).  320 
 321 
3.6 Correlation between IGF2 and other markers  322 
The correlation between the expression levels of IGF2 and CD133, and that between 323 
IGF2 and miR-377 were determined in 47 pairs of ESCC and corresponding adjacent non-324 
tumorous tissues, which were previously assayed for IGF2 and CD133 using western blotting 325 
and for miR-377 using qRT-PCR [9, 18]. The results showed that the expression levels of 326 
IGF2 and CD133 were positively correlated, whereas IGF2 and miR-377 were negatively 327 
correlated (Figure 6A). Further analysis based on TCGA data revealed that IGF2 and CD133 328 
were positively correlated in several other cancer types (Figure 6B).  329 
 330 
  331 
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4. Discussion 332 
IGF2 has been reported to play a very precise function in adult hematopoietic stem 333 
cell homeostasis [24].  However, there is little information about its role in cancer stem cells. 334 
The ability to initiate tumor and self-renew are well-recognized characteristics of CSCs. Here, 335 
we showed for the first time that IGF2 can drive stemness in ESCC, as evidenced by its 336 
ability to potentiate and maintain the self-renewal capacity of ESCC cells during serial 337 
passaging. The results of the present study also demonstrated that IGF2 upregulates CD133, 338 
which is a functional CSC marker in ESCC [9]. Surprisingly, relatively little is known about 339 
the upstream regulation of CD133 despite it being a widely accepted stem cell marker. 340 
Increasing evidence suggests the important roles for noncoding RNAs in cancer stem cells 341 
[25, 26]. One study showed that growth and self-renewal of CD133-positive liver CSCs are 342 
regulated by miR-230b via tumor protein 53-induced nuclear protein 1 [5]. CD133-positive 343 
liver and brain CSCs have been reported to be dependent on STAT3 signaling to promote 344 
chemoresistance and drive medulloblastoma recurrence [27, 28]. A recent study showed that 345 
CD133 confers cancer stem-like cell properties by stabilizing EGFR-AKT signaling in 346 
hepatocellular carcinoma [29]. In our present study, we found that IGF2 increased CD133 347 
expression through downregulation of miR-377 expression in a PI3K/AKT-dependent 348 
manner (Figures 1-3). Immunohistochemical analysis of a tissue microarray confirmed that 349 
the expression levels of IGF2 and CD133 were significantly correlated in ESCC tissues and 350 
more importantly, the data showed that patients with concurrent elevation of IGF2 and 351 
CD133 expressions in their primary tumors have particularly poor prognosis (Figure 5). By 352 
analyzing the TCGA data, we also showed that a positive correlation between IGF2 and 353 
CD133 is common in several other cancer types (Figure 6). 354 
Data from our previous studies showed that a CD133
-
 ESCC cell line expresses IGF2 355 
and p-AKT [9, 18, 21] which suggests that the IGF2-PI3K/AKT part of the IGF2-PI3K/AKT-356 
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miR-377-CD133 axis is operative in CD133
-
 cells although the mechanisms downstream of 357 
PI3K/AKT that promote tumorigenicity in these cells may be different from that of CD133
+
 358 
cells. It should be noted that in addition to CD133, a number of promising markers of 359 
esophageal CSCs have been documented, e.g. CD90, ALDH1, Lgr5, CD44; overlapping 360 
expression of stem cell markers is also very common [30, 31]. CD90
+
 esophageal cancer cells, 361 
for example, have an aggressive signature and metastatic capacity [32]. It was reported that 362 
the NFκB signaling pathway contributes to the acquisition of CSC-like phenotype of CD90
+
 363 
cells [33]. It is possible that CD133
-
 cells express CD90, in which case the mechanisms 364 
underlying CSC-like phenotype of CD90
+
 cells may apply. Nevertheless, the delineation of 365 
an IGF2-PI3K/AKT-miR-377-CD133 signaling pathway (Figure 3H) not only provides new 366 
insight into the ESCC tumorigenic process, but also reveals a cascade of potential therapeutic 367 
targets that may be exploited to effectively eradicate esophageal CSCs. At the top of this 368 
cascade, IGF2 is increasingly recognized as an attractive therapeutic target due to its 369 
important role in cancer [34]. IGF2 signals through type-1 insulin-like growth factor receptor 370 
(IGF1R), which is one of the crucial receptor tyrosine kinases implicated in the development 371 
of gastroenteropancreatic neuroendocrine neoplasms [35]. Currently, the available agents 372 
targeting IGF2 signaling include small-molecule tyrosine kinase inhibitor against IGF1R (e.g. 373 
linsitinib), monoclonal antibodies against IGF1R (e.g. ganitumab, dalotuzumab, figitumumab, 374 
cixutumumab), and blocking antibodies against IGF (MEDI-573 and BI 836845) [36]. 375 
Several multi-center single or combinational Phase I/II studies of these agents are still 376 
ongoing and more favorable outcomes are expected to be revealed in the near future. 377 
Ganitumab, a fully human antibody against IGF1R, for example, is well tolerated and has 378 
antitumor activity in patients with metastatic Ewing family tumors or desmoplastic small 379 
round cell tumors [37]. Cixutumumab, another fully human monoclonal antibody targeting 380 
IGF1R, which we found to have significant suppressive effects on human ESCC tumor 381 
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xenografts in nude mice [12], was reported to be well-tolerated and active in relapsed 382 
thymoma in a phase II trial [38]. The results of our present study corroborates that treatment 383 
with IGF2-neutralizing antibody can inhibit the abilities of CD133-positive ESCC cells to 384 
initiate tumor, self-renew, and resist chemotherapeutic drugs (Figure 2 and Figure 4). 385 
Likewise, PI3K/AKT inhibitors previously shown to inhibit chemoresistance and metastasis 386 
of ESCC [20, 21] were found to be effective in suppressing stemness of CD133-positive 387 
CSCs. MicroRNAs can function as negative regulators of target genes by inducing 388 
translational repression and mRNA degradation. They are increasingly recognized as useful 389 
predictive biomarkers and therapeutic targets for cancer [39]. In this study, we showed that 390 
miR-377 mediates the effects of IGF2 on CD133 expression and CSC properties (Figure 3). 391 
In conclusion, our new findings not only provide mechanistic insight into the 392 
regulatory functions of the IGF2-PI3K/AKT-miR-377-CD133 signaling pathway in tumor 393 
initiation, but also rationalize the clinical application of PI3K/AKT inhibitors and IGF2 394 
antibody therapy in targeting tumor-initiating cells and treating human cancer.  395 
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7. Figure Legends 544 
Figure 1. IGF2 is essential for maintenance of CSC properties in esophageal cancer. (A) 545 
Comparison of tumorigenicity of KYSE270-shCON and KYSE270-shIGF2#2 cells in nude 546 
mice. (B) Tumor incidence in nude mice during serial passage of KYSE270-shCON cells 547 
(left flank, black arrow) and KYSE270-shIGF2#2 cells (right flank, white arrow) inoculated 548 
at a dose of 2x10
4
 cells. Representative photos of mice bearing subcutaneous tumors taken 60 549 
days after subcutaneous inoculation of cancer cells are shown below. (C) IGF2 (50 ng/ml) 550 
significantly enhanced serial propagation of tumor spheres in esophageal cancer cells, but 551 
addition of LY294002 (5 μM) abolished this effect. (D) Effect of IGF2-knockdown on the 552 
ability of esophageal cancer cells to initiate and form tumor spheres over serial passages. (E) 553 
Two ESCC cell lines were treated with 50 ng/ml IGF2 in the presence or absence of 5 μM 554 
LY294002 for 48 h, and the expression levels of p-AKT, AKT, and CD133 were detected by 555 
western blot. (F) Knockdown of IGF2 markedly reduced CD133 expression. Bars, SD; *, P < 556 
0.05; **, P < 0.01 compared with the control cells. 557 
 558 
Figure 2. Effects of PI3K/AKT inhibition on the ability of CD133
+
 ESCC cells to self renew, 559 
form tumors, and resist chemotherapeutic drugs. (A) Sphere-forming ESCC cells and 560 
adherent counterparts were compared for p-AKT and AKT expressions by western blot. (B, 561 
C) Treatment with wortmannin or LY294002 for 72 h (B), and PTEN-overexpression (C) 562 
resulted in marked reduction of CD133 expression in ESCC cells. (D) CD133
+
 KYSE270 563 
cells were more sensitive to PI3K inhibitors wortmannin (10 µM) and LY294002 (10 µM) 564 
than CD133
-
 cells. (E, F) Treatment with wortmannin (5 µM) or LY294002 (5 µM) 565 
significantly suppressed serial sphere formation ability (E), and reduced CD133 expression in 566 
sorted CD133
+





 KYSE270 cells were treated with 0.6 mg/kg wortmannin twice a week for 3 weeks 568 
(n = 6). (H) Comparison of the ability of CD133
+
 KYSE270 cells to form spheres in the 569 
presence of 5-FU (10 µM), DDP (40 µM), wortmannin (2.5 µM), or a combination of 570 
wortmannin and 5-FU or DDP. DMSO-treated cells served as control. Bars, SD; *, P< 0.05; 571 
**, P < 0.01; ***, P < 0.001. 572 
 573 
Figure 3. IGF2 stimulates PI3K/AKT pathway, which reduces miR-377 expression, to 574 
upregulate CD133. (A) KYSE270 and T.Tn cells were treated with wortmannin (left panel) 575 
or transfected with PTEN (right panel), and qRT-PCR was performed to determine the miR-576 
377 expression level relative to that of corresponding controls. (B) qRT-PCR analysis of 577 
miR-377 expression in the KYSE270 and T.Tn cells treated with IGF2 (50 ng/ml) in the 578 
presence or absence of LY294002 (5 μM). (C) Effect of IGF2-knockdown on miR-377 579 
expression in KYSE270 and T.Tn cells. (D) Analyses of expression levels of miR-377 (left 580 
panel), p-AKT, AKT, and CD133 (right panel) in the tumor xenografts of KYSE270-shCON 581 
and KYSE270-shIGF2#2 cells (Figure 1A) by qRT-PCR and western blot, respectively. (E) 582 
Western blot analysis of CD133 expression in the ESCC cells treated with IGF2 (50 ng/ml) 583 
with or without miR-377 transfection (50 nM). (F, G) The ESCC cells with IGF2-knockdown 584 
were transfected with miR-377 inhibitor or the corresponding control (miRNA inhibitor NC), 585 
and then compared with the control cells for the abilities to resist 5-FU treatment (F) and to 586 
form spheres over serial passages (G). (H) Proposed model illustrating the mechanism of 587 
IGF2 in regulating CD133 expression and CSC properties in ESCC. Bars, SD; * P < 0.05; **, 588 




Figure 4. Therapeutic efficacy of IGF2-neutralizing antibody in suppressing ESCC 591 
tumorigenicity and chemoresistance in vivo. (A) Comparison of the ability of ESCC cells to 592 
form spheres in the presence of different doses of IGF2-neutralizing antibody. Note that 593 
neutralizing antibody against IGF2 inhibited propagation of tumor spheres over serial 594 
passages. (B) Growth curves of subcutaneous KYSE270 tumors in nude mice treated with 595 
IGF2-neutralizing antibody. (C) Expression level of miR-377 and protein expression levels of 596 
p-AKT, AKT, CD133 were determined by qRT-PCR and western blot, respectively. (D) 597 
Treatment with IGF2-neutralizing antibody significantly enhanced the sensitivity of 598 
KYSE270 tumor xenografts to 5-FU in nude mice. Bars, SD; * P < 0.05; **, P < 0.01; ***, P 599 
< 0.001 compared with controls. 600 
 601 
Figure 5. Clinicopathological significance of IGF2 and CD133 expressions in ESCC. (A) 602 
Representative images of ESCC with immunohistochemical staining scores of 0 to 3 for IGF2. 603 
(B) Immunostaining scores for IGF2 expression in 100 cases of tumors and 80 cases of 604 
normal tissues. The mean values are represented by the horizontal lines. An example of a 605 
primary ESCC with higher immunohistochemical expression of IGF2 compared with 606 
matched normal epithelium is included below the graph. (C) Representative images of 607 
CD133-negative and CD133-positive tumors (upper panel). An example of CD133 staining in 608 
paired primary ESCC tissue and non-tumor tissues (lower panel). (D) CD133 expression 609 
status in 100 cases of ESCC and 80 cases of normal tissues. (E)  Kaplan-Meier plots were 610 
used to compare overall survival of 100 patients with ESCC stratified according to IGF2 611 
expression level (left panel), CD133 expression status (middle panel), and different IGF2 and 612 




Figure 6. Relationship between IGF2 levels and expression of other markers. (A) 615 
Correlations between IGF2 and CD133, and between IGF2 and miR-377 in 47 pairs of ESCC 616 
and normal tissues. (B) Correlation between IGF2 and CD133 in other cancer types based on 617 
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Table 1. Correlation between IGF2 expression levels and clinicopathological parameters in 





Variable n Low IGF2 High IGF2 P value 
Age ( years)         
≤55 19 8 11  
>55 81 40 41 0.617 
      
Gender     
Female 26 16 10  
Male 74 32 42 0.117 
      
     
T-Stage     
1/2 15 11 4  
3/4 82 35 47 0.047* 
      
N-Stage     
N0 46 27 19  
N1 54 21 33 0.070 
      
M-Stage     
M0 99 48 51  
M1 0 0 0 1.000 
      
Pathologic stage     
Stages I & II 75 34 41  
Stages III & IV 25 14 11 0.367 
      
          
 




Table 2. Correlation between CD133 expression levels and clinicopathological parameters in 
100 cases of ESCC. 
 
Variable n Low CD133 High CD133 P value 
Age ( years)         
≤55 19 14 5  
>55 81 41 40 0.078 
      
Gender     
Female 26 14 12  
Male 74 41 33 1.000 
      
     
T-Stage     
1/2 15 12 3  
3/4 82 40 42 0.046* 
      
N-Stage     
N0 46 27 19  
N1 54 28 26 0.548 
      
M-Stage     
M0 99 54 45  
M1 0 0 0 1.000 
      
Pathologic stage     
Stages I & II 75 43 32  
Stages III & IV 25 12 13 0.489 
      
          
 




Table 3. Correlation between CD133/IGF2 expression levels and clinicopathological 











 P value 
Age ( years)         
≤55 9 6 3  
>55 53 26 27 0.475 
      
Gender     
Female 18 11 7  
Male 44 21 23 0.407 
      
     
T-Stage     
1/2 8 8 0  
3/4 52 22 30 0.005** 
      
N-Stage     
N0 26 16 10  
N1 36 16 20 0.208 
      
M-Stage     
M0 60 28 32  
M1 0 0 0 1.000 
      
Pathologic stage     
Stages I & II 45 23 22  
Stages III & IV 17 9 8 1.000 
      
          
 
    
Table 3
Table 4. Cox proportional hazard regression analysis of CD133 and IGF2 expressions for 
overall survival. 
 
      Clinical features Univariate analysis   Multivariate analysis 
 
HR (95% CI) P Value 
 
HR (95% CI) P Value 
Age 
(<55 years vs >55 years) 




(male vs female) 




(1/2 vs 3/4) 




(N0 vs N1) 
2.243 (1.245-4.040) 0.007 
 
1.984 (1.095-3.597) 0.024 
M-stage 
(M0 vs M1) 
- -  - - 
Pathological stage 
(I & II vs III & IV) 












2.392 (1.365-4.190) 0.002   2.146 (1.217-3.782) 0.008 
      
 
HR, Hazard ratio; CI, Confidence interval 
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Supplementary Figure 1.  Effects of (A) PI3K inhibitors and (B) PTEN expression 






























































Supplementary Figure 2. (A)  Western blot showing the expression of CD133, IGF2, 
p-AKT and AKT in CD133-positive and -negative cells. (B）Taqman assay showing 
the expression of miR-377 in CD133-positive and -negative cells.
